Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of sirukumab in severe, poorly controlled asthma
2016-001244-19Phase 2Terminated
- Sponsor
- GSK
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing Sirukumab with Placebo (2 arms). Primary endpoint: Change from baseline in ACQ-7 at week 24. Started Jul 2016; status: terminated.
02
Drugs
sirukumab
03
Conditions
asthma
Beyond the preview
Go deeper on 2016-001244-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001244-19.